文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

地拉罗司治疗芦可替尼治疗的骨髓纤维化患者铁过载:多中心回顾性RUX-IOL研究

Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study.
PubMed 文献 · Br J Haematol · 2022-02-08

RUX-IOL研究回顾性纳入69例接受芦可替尼(RUX)联合地拉罗司(DFX)治疗铁过载(IOL)的骨髓纤维化(MF)患者,评估联合治疗的安全性、铁螯合反应(ICR)与红系反应(ER)及对总生存的影响。中位治疗12.4个月,未报告意外毒性;ICR 33例(47.8%)、ER 32例(46.4%),13例(18.9%)脱离输血。多变量分析中基线无白细胞增多(p=0.02)和任何时间达到ICR(p=0.02)预测生存改善。

要点

  • RUX-DFX联合治疗中位12.4个月,未报告意外毒性。
  • ICR 33例(47.8%),ER 32例(46.4%),13例(18.9%)脱离输血。
  • 基线无白细胞增多和达到ICR预测生存改善(均p=0.02)。

核心结论

  • 在许多MF患者中,RUX-DFX联合治疗提供了与结局改善相关的ICR和ER反应,且未出现意外毒性。
  • 该策略值得进一步临床研究。

研究设计与样本

  • 多中心回顾性RUX-IOL研究,回顾性收集69例接受芦可替尼(RUX)联合地拉罗司(DFX)治疗铁过载(IOL)的骨髓纤维化(MF)患者。
  • 评估安全性、铁螯合反应(ICR)与红系反应(ER)及联合治疗对总生存的影响。

主要发现

  • RUX-DFX治疗中位时间12.4个月(四分位距3.1-71.2)。
  • 治疗期间36例(52.2%)和34例(49.3%)患者分别需要RUX和DFX减量,8例(11.6%)和9例(13.1%)患者分别因RUX或DFX相关不良事件停药;未报告意外毒性。
  • ICR和ER分别由33例(47.8%)和32例(46.4%)患者达到;13例(18.9%)患者脱离输血。
  • 达到ICR和ER的中位时间分别为6.2个月和2个月;达到ER的患者也更可能获得ICR(p=0.04)。
  • 多变量分析中,基线无白细胞增多(p=0.02)和任何时间达到ICR(p=0.02)预测生存改善。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文为回顾性研究。
  • 原文结论提出该策略值得进一步临床研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Deferasirox (DFX) is used for the management of iron overload (IOL) in many haematological malignancies including myelofibrosis (MF). The 'RUX-IOL' study retrospectively collected 69 MF patients treated with ruxolitinib (RUX) and DFX for IOL to assess: safety, efficacy in term of iron chelation response (ICR) and erythroid response (ER), and impact on overall survival of the combination therapy. The RUX-DFX therapy was administered for a median time of 12.4 months (interquartile range 3.1-71.2). During treatment, 36 (52.2%) and 34 (49.3%) patients required RUX and DFX dose reductions, while eight (11.6%) and nine (13.1%) patients discontinued due to RUX- or DFX-related adverse events; no unexpected toxicity was reported. ICR and ER were achieved by 33 (47.8%) and 32 patients (46.4%) respectively. Thirteen (18.9%) patients became transfusion-independent. Median time to ICR and ER was 6.2 and 2 months respectively. Patients achieving an ER were more likely to obtain an ICR also (p = 0.04). In multivariable analysis, the absence of leukocytosis at baseline (p = 0.02) and achievement of an ICR at any time (p = 0.02) predicted improved survival. In many MF patients, the RUX-DFX combination provided ICR and ER responses that correlated with improved outcome in the absence of unexpected toxicities. This strategy deserves further clinical investigation.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Elli EM, Di Veroli A, Bartoletti D, et al. Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study. Br J Haematol. 2022. PMID: 35137397. doi:10.1111/bjh.18057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。